(NASDAQ: IKNA) Ikena Oncology's forecast annual revenue growth rate of 48.45% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Ikena Oncology's revenue in 2024 is $9,160,000.On average, 3 Wall Street analysts forecast IKNA's revenue for 2024 to be $492,232,732, with the lowest IKNA revenue forecast at $48,258,111, and the highest IKNA revenue forecast at $752,826,532. On average, 2 Wall Street analysts forecast IKNA's revenue for 2025 to be $965,162,220, with the lowest IKNA revenue forecast at $965,162,220, and the highest IKNA revenue forecast at $965,162,220.
In 2026, IKNA is forecast to generate $1,447,743,330 in revenue, with the lowest revenue forecast at $965,162,220 and the highest revenue forecast at $1,930,324,440.